vorinostat

vorinostat information and resources from the National Cancer Institute

NCI Thesaurus | vorinostat

A synthetic agent with antineoplastic properties. Vorinostat, also known as suberoylanilide hydroxamic acid (SAHA), inhibits the enzyme histone deacetylase (HDAC), induces differentiation in some cell types, and has been shown to induce p53-independent apoptosis in a number of tumor cell lines. This agent crosses the blood-brain barrier. NCI Thesaurus | vorinostat

A synthetic agent with antineoplastic properties. Vorinostat, also known as suberoylanilide hydroxamic acid (SAHA), inhibits the enzyme histone deacetylase (HDAC), induces differentiation in some cell types, and has been shown to induce p53-independent apoptosis in a number of tumor cell lines. This agent crosses the blood-brain barrier.

Merck cites new cholesterol drugs, boosts cost cuts Dec 15, 2005
Reuters ...to ask US regulators to approve Januvia as a stand-alone treatment for type 2 diabetes, and seek approvals for a lymphoma treatment called vorinostat and the ...

Merck Refills its Prescription Dec 15, 2005
Red Herring, Merck plans to submit applications in 2006 for Januvia, a treatment for Type 2 diabetes; vorinostat, a histone deacetylase inhibitor for cancer; and MK-517, a ...

Merck Unveils Plan to Reclaim Leadership Position Dec 15, 2005
Business Wire (press release), FDA filings: JANUVIA (the proposed trademark for the compound known as MK-431), a novel mechanism for the treatment of Type 2 diabetes; vorinostat (the generic ...

Merck Unveils Plan to Reclaim Leadership Position Dec 15, 2005
Finanzen.net, ...filings: JANUVIA(the proposed trademark for the compound known as MK-431), a novelmechanism for the treatment of Type 2 diabetes; vorinostat (thegeneric name ...

Merck boosts cost cuts by $1 billion Dec 16, 2005
Pharma Times (subscription), Merck said it anticipates three additional new product filings next year, including: Januvia (MK-431) for type 2 diabetes; vorinostat, a histone deacetylase ...

vorinostat -->